Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes.
Benoît DéchelotteSergio Muñiz-CastrilloBastien JoubertAlberto VogrigGéraldine PicardVéronique RogemondAnne-Laurie PintoChristine LombardVirginie DesestretNicole FabienJérôme HonnoratPublished in: Neurology(R) neuroimmunology & neuroinflammation (2020)
The study provides Class IV evidence that immunodot assays for onconeural antibodies accurately identify patients with paraneoplastic neurologic syndromes.
Keyphrases